<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>It is well documented that high therapeutic doses of oxazaphosphorines, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CP) and ifosfamide (IFO), are associated with <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This study investigated whether oxazaphosphorines alter the expression of <z:chebi fb="0" ids="25697">organic cation</z:chebi>/<z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> transporter (OCTN2) and <z:chebi fb="11" ids="22586">antioxidant</z:chebi> genes and if so, whether these alterations contribute to CP and IFO-induced cardiotoxicity </plain></SENT>
<SENT sid="2" pm="."><plain>Adult male Wistar <z:mp ids='MP_0001189'>albino</z:mp> rats were assigned to one of six treatment groups namely, control, L <z:chebi fb="1" ids="16347,3424">carnitine</z:chebi>, CP, IFO, CP plus L <z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> and IFO plus L <z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>In cardiac and kidney tissues, CP and IFO significantly decreased <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein expression of OCTN2 </plain></SENT>
<SENT sid="4" pm="."><plain>Oxazaphosphorines significantly increased serum acyl-<z:chebi fb="1" ids="16347,3424">carnitine</z:chebi>/free <z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> ratio and urinary <z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> excretion and significantly decreased total <z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> in cardiac tissues </plain></SENT>
<SENT sid="5" pm="."><plain>Interestingly, <z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> supplementation completely reversed the biochemical and gene expression changes-induced by oxazaphosphorines to the control values, except OCTN2 expression remained inhibited by IFO </plain></SENT>
<SENT sid="6" pm="."><plain>Data from this study suggest that: (1) Oxazaphosphorines decreased myocardial <z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> content following the inhibition of OCTN2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein expression in cardiac tissues </plain></SENT>
<SENT sid="7" pm="."><plain>(2) Oxazaphosphorine therapy increased urinary loss of <z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> secondary to the inhibition of OCTN2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein expression in proximal tubules of the kidney </plain></SENT>
<SENT sid="8" pm="."><plain>(3) <z:chebi fb="1" ids="16347,3424">Carnitine</z:chebi> supplementation attenuates CP but not IFO-induced inhibition of OCTN2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein expression in heart and kidney tissues </plain></SENT>
</text></document>